Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an autoimmune disorder characterized by the progressive damage to the peripheral nerves, leading to weakness and sensory loss.

Emerging data suggest a possible genetic contributor to CIDP. In a recent study, patients with CIDP had a high frequency of perforin gene variations that impair the function of cytotoxic T and ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) affects the peripheral nerves. Tests to diagnose this condition include nerve conduction studies, electromyography, and sometimes an MRI.

Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic immune-mediated neuropathy. It affects ...

Chronic inflammatory demyelinating polyneuropathy is an immune-mediated neuropathy that affects the peripheral motor and sensory nerves. The symptoms are of a slowly progressive numbness and tingling ...

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) diagnoses are frequently missed or delayed and standard treatments - ...

Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug t ...

Background: Chronic inflammatory demyelinating polyradiculoneuropathy is a rare acquired immune-mediated progressive or relapsing disorder causing peripheral neuropathic disease of duration more ...

Polyneuropathy occurs when multiple peripheral nerves become damaged. Symptoms include problems with sensation, coordination, or other body functions. Polyneuropathy is also known as peripheral ...

THE family of a "beloved father and husband" who took his own life after Covid-19 vaccine complications are fighting for justice.

(RTTNews) - argenx SE (ARGX) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) approved VYVDURA for adults with chronic inflammatory demyelinating polyneuropathy. VYVDURA is ...